Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4] by Quarter
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M) ($M)
Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4]: $0M in Q4 2024, down 100.0% from a year earlier. That is the lowest of the 20 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2024 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2025-02-13) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2024 | Dec 29, 2024 | 0 | -100.0% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2024 | Sep 29, 2024 | 1 | -97.6% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2024 | Jun 30, 2024 | 172 | -39.6% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2024 | Mar 31, 2024 | 25 | -96.7% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 44 | -93.6% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2023 | Oct 1, 2023 | 41 | -91.6% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 285 | -47.6% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 747 | +63.5% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 689 | -57.4% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 489 | -2.6% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 544 | +231.7% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 457 | +357.0% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 1,619 | – | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 502 | – | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 164 | – | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 100 | – | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 0 | – | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 0 | – | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 0 | – | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 0 | – | Form 10-Q (filed 2021-04-30) ↗ |
Breakdown
What makes up COVID-19 Vaccine [reported through FY2024Q4]
- COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — U.S. sales ($M)0 · Q4 2024
- COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M)0 · Q4 2024
- COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%)-97.7% · Q3 2024
- COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide operational (constant-currency) growth YoY (%)-98.9% · Q3 2024
Cite this data
StockData. (2026). Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4] ($M), quarterly Q1 2020–Q4 2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-covid19
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.